Inovio Pharmaceuticals Inc INO

Healthcare Biotechnology

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.

NDAQ:INO - Post by User

Inovio Pharmaceuticals Inc > Question

<< Previous

Bullboard Posts

Next >>

Comment by bubba9on Jun 25, 2020 3:40pm

76 Views

Post# 31192061

RE:Question

Day traders trade shares multiple times in a day. MULTIPLE. ....

FLYIN wrote: I checked the public float and there is 158 million shares, yet the volume was 170 million yesterday, so how is this possible?
thanks
Flyin

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions